BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2026 9:17:09 AM | Browse: 6 | Download: 29
 |
Received |
|
2025-12-30 05:59 |
|
Peer-Review Started |
|
2025-12-30 05:59 |
|
First Decision by Editorial Office Director |
|
2026-01-06 07:10 |
|
Return for Revision |
|
2026-01-06 07:10 |
|
Revised |
|
2026-01-12 14:12 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-09 02:47 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-09 08:41 |
|
Articles in Press |
|
2026-02-09 08:41 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-24 09:29 |
|
Publish the Manuscript Online |
|
2026-05-14 09:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Feng Chi, Chi-Bo Liu, Jian Li, Xian-Wu Xia, Qian-Jin Hua and Wei Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wei Wang, MD, Research Dean, Researcher, Department of Interventional Oncology, Municipal Hospital Affiliated to Taizhou University, No. 581 Shifu Avenue East, Jiaojiang District, Taizhou 318000, Zhejiang Province, China. wangw@tzc.edu.cn |
| Key Words |
Adoptive cell therapy; Anti-angiogenic therapy; Biomarkers; Immune checkpoint inhibitors; Immune exclusion; Microsatellite-stable colorectal cancer; Tumor microenvironment; Vaccine |
| Core Tip |
Most colorectal cancers are microsatellite-stable (MSS)/proficient mismatch repair and remain largely refractory to single-agent immune checkpoint inhibitors. This review dissects major resistance determinants low neoantigen burden, impaired antigen presentation, immune exclusion by cancer-associated fibroblast-rich stroma and abnormal vasculature, and myeloid-dominant suppression, particularly in liver metastases. We synthesize current evidence for rational “cold-to-hot” strategies, spanning chemo/radiotherapy priming, anti-angiogenic and anti-epidermal growth factor receptor regimens, mitogen-activated protein kinase/Wnt/transforming growth factor-β/CXCR4-signal transducer and activator of transcription 3 pathway targeting, and emerging vaccines, oncolytic viruses, cell therapies, and microbiome modulation. A biomarker-guided roadmap is proposed to personalize combination immunotherapy in MSS colorectal cancer. |
| Publish Date |
2026-05-14 09:17 |
| Citation |
Chi F, Liu CB, Li J, Xia XW, Hua QJ, Wang W. Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy. World J Gastrointest Oncol 2026; 18(5): 118319 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i5/118319.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i5.118319 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
